Literature DB >> 22623788

Arenavirus nucleoproteins prevent activation of nuclear factor kappa B.

W W Shanaka I Rodrigo1, Emilio Ortiz-Riaño, Christelle Pythoud, Stefan Kunz, Juan C de la Torre, Luis Martínez-Sobrido.   

Abstract

Arenaviruses include several causative agents of hemorrhagic fever (HF) disease in humans that are associated with high morbidity and significant mortality. Morbidity and lethality associated with HF arenaviruses are believed to involve the dysregulation of the host innate immune and inflammatory responses that leads to impaired development of protective and efficient immunity. The molecular mechanisms underlying this dysregulation are not completely understood, but it is suggested that viral infection leads to disruption of early host defenses and contributes to arenavirus pathogenesis in humans. We demonstrate in the accompanying paper that the prototype member in the family, lymphocytic choriomeningitis virus (LCMV), disables the host innate defense by interfering with type I interferon (IFN-I) production through inhibition of the interferon regulatory factor 3 (IRF3) activation pathway and that the viral nucleoprotein (NP) alone is responsible for this inhibitory effect (C. Pythoud, W. W. Rodrigo, G. Pasqual, S. Rothenberger, L. Martínez-Sobrido, J. C. de la Torre, and S. Kunz, J. Virol. 86:7728-7738, 2012). In this report, we show that LCMV-NP, as well as NPs encoded by representative members of both Old World (OW) and New World (NW) arenaviruses, also inhibits the nuclear translocation and transcriptional activity of the nuclear factor kappa B (NF-κB). Similar to the situation previously reported for IRF3, Tacaribe virus NP (TCRV-NP) does not inhibit NF-κB nuclear translocation and transcriptional activity to levels comparable to those seen with other members in the family. Altogether, our findings demonstrate that arenavirus infection inhibits NF-κB-dependent innate immune and inflammatory responses, possibly playing a key role in the pathogenesis and virulence of arenavirus.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22623788      PMCID: PMC3421694          DOI: 10.1128/JVI.07240-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  96 in total

1.  Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon.

Authors:  X Wang; M Li; H Zheng; T Muster; P Palese; A A Beg; A García-Sastre
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  VISA is an adapter protein required for virus-triggered IFN-beta signaling.

Authors:  Liang-Guo Xu; Yan-Yi Wang; Ke-Jun Han; Lian-Yun Li; Zhonghe Zhai; Hong-Bing Shu
Journal:  Mol Cell       Date:  2005-09-16       Impact factor: 17.970

3.  Transmission of lymphocytic choriomeningitis virus by organ transplantation.

Authors:  Staci A Fischer; Mary Beth Graham; Matthew J Kuehnert; Camille N Kotton; Arjun Srinivasan; Francisco M Marty; James A Comer; Jeannette Guarner; Christopher D Paddock; Dawn L DeMeo; Wun-Ju Shieh; Bobbie R Erickson; Utpala Bandy; Alfred DeMaria; Jeffrey P Davis; Francis L Delmonico; Boris Pavlin; Anna Likos; Martin J Vincent; Tara K Sealy; Cynthia S Goldsmith; Daniel B Jernigan; Pierre E Rollin; Michelle M Packard; Mitesh Patel; Courtney Rowland; Rita F Helfand; Stuart T Nichol; Jay A Fishman; Thomas Ksiazek; Sherif R Zaki
Journal:  N Engl J Med       Date:  2006-05-25       Impact factor: 91.245

Review 4.  Convergence of the NF-kappaB and IRF pathways in the regulation of the innate antiviral response.

Authors:  John Hiscott
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-13       Impact factor: 7.638

5.  Therapeutic effect of the antiviral agent ribavirin in Junín virus infection of primates.

Authors:  M C Weissenbacher; M A Calello; M S Merani; J B McCormick; M Rodriguez
Journal:  J Med Virol       Date:  1986-11       Impact factor: 2.327

6.  IKK-i signals through IRF3 and NFkappaB to mediate the production of inflammatory cytokines.

Authors:  Sabita Sankar; Henry Chan; William J Romanow; Jianwu Li; R J Bates
Journal:  Cell Signal       Date:  2005-09-30       Impact factor: 4.315

7.  Lymphocytic choriomeningitis virus: an underdiagnosed cause of congenital chorioretinitis.

Authors:  M B Mets; L L Barton; A S Khan; T G Ksiazek
Journal:  Am J Ophthalmol       Date:  2000-08       Impact factor: 5.258

8.  Mechanism of lymphocytic choriomeningitis virus entry into cells.

Authors:  P Borrow; M B Oldstone
Journal:  Virology       Date:  1994-01       Impact factor: 3.616

9.  Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP).

Authors:  Robert Eichler; Thomas Strecker; Larissa Kolesnikova; Jan ter Meulen; Winfried Weissenhorn; Stephan Becker; Hans Dieter Klenk; Wolfgang Garten; Oliver Lenz
Journal:  Virus Res       Date:  2004-03-15       Impact factor: 3.303

10.  Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation.

Authors:  Igor S Lukashevich; Ilia Tikhonov; Juan D Rodas; Juan C Zapata; Yida Yang; Mahmoud Djavani; Maria S Salvato
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more
  56 in total

1.  Lymphocytic Choriomeningitis Virus Differentially Affects the Virus-Induced Type I Interferon Response and Mitochondrial Apoptosis Mediated by RIG-I/MAVS.

Authors:  Christelle Pythoud; Sylvia Rothenberger; Luis Martínez-Sobrido; Juan Carlos de la Torre; Stefan Kunz
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

2.  Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKKε.

Authors:  Christelle Pythoud; W W Shanaka I Rodrigo; Giulia Pasqual; Sylvia Rothenberger; Luis Martínez-Sobrido; Juan Carlos de la Torre; Stefan Kunz
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

3.  Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.

Authors:  Benson Yee Hin Cheng; Emilio Ortiz-Riaño; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

4.  The IκB Kinases Restrict Human Cytomegalovirus Infection.

Authors:  Christopher M Goodwin; Joshua Munger
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

5.  The exonuclease domain of Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell responses.

Authors:  Marion Russier; Stéphanie Reynard; Xavier Carnec; Sylvain Baize
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

6.  Exonuclease domain of the Lassa virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response.

Authors:  Stéphanie Reynard; Marion Russier; Alexandra Fizet; Xavier Carnec; Sylvain Baize
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

7.  Development of live-attenuated arenavirus vaccines based on codon deoptimization.

Authors:  Benson Yee Hin Cheng; Emilio Ortiz-Riaño; Aitor Nogales; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

8.  Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice.

Authors:  Masaharu Iwasaki; Cherie T Ng; Beatrice Cubitt; Juan C de la Torre
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

9.  Activation of the RLR/MAVS Signaling Pathway by the L Protein of Mopeia Virus.

Authors:  Lei-Ke Zhang; Qi-Lin Xin; Sheng-Lin Zhu; Wei-Wei Wan; Wei Wang; Gengfu Xiao
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

10.  Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor.

Authors:  Emilio Ortiz-Riaño; Nhi Ngo; Stefanie Devito; Dirk Eggink; Joshua Munger; Megan L Shaw; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.